Study type: In vivo/preclinical · Status: Verified against declared source
Vasodilatory effect of the stable vasoactive intestinal chemical sequence analog RO 25-1553 in murine and rat lungs.
PloS one · 2013
Study scale: Not reported
Abstract only: Open source record
Product or molecular entity relationships
- VIP: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
In the present study, we aimed to evaluate the vasodilatory potential of the synthetic, stable VIP analog RO 25-1553 in the pulmonary circulation.
Methods
In a second set of experiments, we tested whether RO 25-1553 exerts a similar vasodilatory effect in the pulmonary vasculature when a) administered by inhalation and b) in an in vivo setting rather than an isolated organ preparation.
Scale or participants
Not reported in the reviewed source.
Key findings
Stable analogs of vasoactive intestinal peptide (VIP) have been proposed as novel line of therapy in chronic obstructive pulmonary disease (COPD) based on their bronchodilatory and anti-inflammatory effects.
Limitations and uncertainty
On the vascular side, VIP or its natural analogs have previously been shown to relax isolated pulmonary artery segments, to antagonize pulmonary vasoconstriction, and to inhibit the proliferation of pulmonary vascular smooth muscle cells from patients with idiopathic pulmonary arterial hypertension [12], [13].
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.